These companies remain strong buys -- even soaring stock prices can't keep up with their stellar business performance.

After a historic bull market run, growth stock opportunities are getting harder to find.

Wall Street expects CoreWeave stock to jump more than 55% over the coming 12 months, making now, right before 2026, a good ...

Opendoor Technologies (NASDAQ: OPEN) is probably not a stock you heard much about last year -- it lost nearly two-thirds of ...

The biotech's investigational weight loss drug did very well in a clinical trial. This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the ...

Quebecor (TSX:QBR.B) has gone parabolic (≈+62% YTD) but still looks like an attractive mid‑cap growth/dividend‑growth pick ...

Sales from the pharmaceutical company's three top drugs are soaring. There are lots of great stocks in this sector. But one ...

Over the past one, three, and five years, Starbucks has notably underperformed the bellwether S&P 500 index. In all three ...

TD Bank (TSX:TD) and other Big Six banks blew reported good results for their latest quarters. Canadian big‑bank fundamentals ...

Jacob Fund is a mutual fund company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded ...